tradingkey.logo

Beta Bionics Inc

BBNX

23.050USD

-0.060-0.26%
Cierre 09/18, 16:00ETCotizaciones retrasadas 15 min
1.00BCap. mercado
PérdidaP/E TTM

Beta Bionics Inc

23.050

-0.060-0.26%
Más Datos de Beta Bionics Inc Compañía
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Información de la empresa
Símbolo de cotizaciónBBNX
Nombre de la empresaBeta Bionics Inc
Fecha de salida a bolsaJan 30, 2025
Director ejecutivoMr. Sean Saint
Número de empleados291
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 30
Dirección11 Hughes
CiudadIRVINE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92618
Teléfono19494277785
Sitio Webhttps://www.betabionics.com
Símbolo de cotizaciónBBNX
Fecha de salida a bolsaJan 30, 2025
Director ejecutivoMr. Sean Saint
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
71.02K
-1.41%
Ms. Christy Jones
Ms. Christy Jones
Independent Director
Independent Director
59.44K
--
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Independent Director
Independent Director
12.55K
--
Mr. Adam Lezack
Mr. Adam Lezack
Independent Chairman of the Board
Independent Chairman of the Board
11.25K
--
Dr. Maria Palasis, Ph.D.
Dr. Maria Palasis, Ph.D.
Independent Director
Independent Director
11.25K
--
Mr. Sean D. Carney
Mr. Sean D. Carney
Independent Director
Independent Director
11.25K
--
Mr. Blake Beber
Mr. Blake Beber
Investor Relations
Investor Relations
--
--
Mr. Sean Saint
Mr. Sean Saint
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-100.00%
Mr. Dan Dearen
Mr. Dan Dearen
Independent Director
Independent Director
--
--
Mr. Stephen Feider
Mr. Stephen Feider
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
71.02K
-1.41%
Ms. Christy Jones
Ms. Christy Jones
Independent Director
Independent Director
59.44K
--
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Independent Director
Independent Director
12.55K
--
Mr. Adam Lezack
Mr. Adam Lezack
Independent Chairman of the Board
Independent Chairman of the Board
11.25K
--
Dr. Maria Palasis, Ph.D.
Dr. Maria Palasis, Ph.D.
Independent Director
Independent Director
11.25K
--
Mr. Sean D. Carney
Mr. Sean D. Carney
Independent Director
Independent Director
11.25K
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2024
FY2023
Por negocioUSD
Nombre
Ganancia
Proporción
DME channel - iLet
46.62M
71.58%
DME channel - Single-use products
12.19M
18.72%
PBP channel - Single-use products
4.22M
6.48%
PBP channel - iLet
2.10M
3.22%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
DME channel - iLet
46.62M
71.58%
DME channel - Single-use products
12.19M
18.72%
PBP channel - Single-use products
4.22M
6.48%
PBP channel - iLet
2.10M
3.22%
Estadísticas de accionistas
Actualizado: mié., 3 de sep
Actualizado: mié., 3 de sep
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Eventide Asset Management, LLC
11.35%
Farallon Capital Management, L.L.C.
9.67%
Wellington Management Company, LLP
8.98%
Soleus Capital Management, L.P.
8.79%
Sands Capital Ventures LLC
8.21%
Otro
53.01%
Accionistas
Accionistas
Proporción
Eventide Asset Management, LLC
11.35%
Farallon Capital Management, L.L.C.
9.67%
Wellington Management Company, LLP
8.98%
Soleus Capital Management, L.P.
8.79%
Sands Capital Ventures LLC
8.21%
Otro
53.01%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
37.10%
Investment Advisor/Hedge Fund
31.62%
Investment Advisor
23.34%
Research Firm
7.39%
Private Equity
3.67%
Venture Capital
1.19%
Individual Investor
0.64%
Sovereign Wealth Fund
0.35%
Pension Fund
0.21%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
161
44.89M
103.27%
+24.04M
2025Q1
149
45.45M
104.86%
+26.05M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Eventide Asset Management, LLC
4.93M
11.37%
+70.98K
+1.46%
Mar 31, 2025
Farallon Capital Management, L.L.C.
3.33M
7.69%
+55.00K
+1.68%
Mar 31, 2025
Wellington Management Company, LLP
3.90M
9%
+3.90M
--
Mar 31, 2025
Soleus Capital Management, L.P.
3.40M
7.83%
+1.10M
+47.92%
Mar 31, 2025
Sands Capital Ventures LLC
3.15M
7.28%
+50.63K
+1.63%
Apr 02, 2025
RTW Investments L.P.
3.30M
7.61%
+200.68K
+6.48%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.39M
3.22%
+1.39M
--
Mar 31, 2025
Omega Fund Management, LLC
1.99M
4.59%
+294.37K
+17.38%
Mar 31, 2025
Perceptive Advisors LLC
2.20M
5.08%
+2.20M
--
Mar 31, 2025
Deerfield Management Company, L.P.
1.02M
2.34%
+1.02M
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: mar., 2 de sep
Actualizado: mar., 2 de sep
Nombre
Proporción
Goldman Sachs Innovate Equity ETF
0.06%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
Schwab U.S. Broad Market ETF
0%
Ver más
Goldman Sachs Innovate Equity ETF
Proporción0.06%
Proshares Ultra Russell 2000
Proporción0.01%
iShares Russell 2000 Growth ETF
Proporción0.01%
Schwab U.S. Small-Cap ETF
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
iShares Russell 2000 ETF
Proporción0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporción0.01%
Schwab U.S. Broad Market ETF
Proporción0%
Dividendos
Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI